NCT06881368 Phenotypic and Etiological Characterization of Susac Syndrome
| NCT ID | NCT06881368 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Susac Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2044-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2025-07-01 with a primary completion date of 2044-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
SUSAC's Syndrome (SS) is characterized by the clinical triad of encephalopathy, hearing loss, and retinal artery branch occlusions. Since the first description of SS in 1979, hundreds of patients with SS, mostly young women, have been reported. However, comprehensive epidemiological, clinical and etiological features of SS have never been specifically addressed so far.
Eligibility Criteria
Inclusion Criteria: * Patient over 18 years of age * Patient presenting with at least two of the signs of the clinical triad: encephalopathy, cochlear damage authenticated by an audiogram (uni- or bilateral, predominantly in the middle or low frequencies), retinal artery occlusion assessed by fundoscopy or fluorescein retinal angiography. Exclusion Criteria: * Patient having been individually informed and objecting to the use of his/her data * Patient under legal protection (guardianship or curatorship) * Differential diagnosis established: multiple sclerosis, mitochondriopathy, CADASIL, primary tumour of the central nervous system, Lyme disease.
Contact & Investigator
Karim Sacre, MD, PHD
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT06881368 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Susac Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06881368 currently recruiting?
Yes, NCT06881368 is actively recruiting participants. Contact the research team at karim.sacre@aphp.fr for enrollment information.
Where is the NCT06881368 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06881368 clinical trial?
NCT06881368 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Karim Sacre, MD, PHD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 180 participants.